BGJ398, a FGFR1-3 inhibitor, was tested in patients with advanced solid tumors including lung, breast, bladder, colon, and liver.183 The phase 1 trial showed that BGJ398 exhibits anti-tumor activity against FGFR1-amplified NSCLC and FGFR3-mutant bladder cancer.183 For precision diagnosis, eligible patients for targeted therapies will be screened and for precision therapy, the targeted drug(s) will be administered at a correct dose to benefit each individual. Here, FGFR3 is linked to non-small cell lung carcinoma.